UBS Group
BCAX

UBS Group’s Bicara Therapeutics BCAX Stock Holding History

UBS Group’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.57M Sell
179,491
-12,700
-7% -$219K ﹤0.01% 4417
2025
Q4 		$3.23M Buy
192,191
+94,829
+97% +$1.62M ﹤0.01% 4478
2025
Q3 		$1.54M Buy
97,362
+9,756
+11% +$109K ﹤0.01% 5209
2025
Q2 		$814K Buy
87,606
+21,752
+33% +$259K ﹤0.01% 5614
2025
Q1 		$858K Sell
65,854
-134,553
-67% -$1.79M ﹤0.01% 5415
2024
Q4 		$3.49M Buy
200,407
+197,617
+7,083% +$4.11M ﹤0.01% 4186
2024
Q3 		$71.1K Buy
+2,790
New +$71.2K ﹤0.01% 6588

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

UBS Group's BCAX Position: Q1 2026 in Review

UBS Group reduced its Bicara Therapeutics (BCAX) stake by 6.6% in Q1 2026, selling an estimated $219K and leaving 179,491 shares worth $3.57M. The position accounts for ﹤0.01% of the portfolio, ranked #4417.

UBS Group first reported a position in BCAX in Q3 2024 and has held it in 7 quarters since. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • UBS Group held 179,491 shares of Bicara Therapeutics worth $3.57M as of Q1 2026.
  • UBS Group sold 12,700 Bicara Therapeutics shares in Q1 2026, an estimated $219K.
  • Bicara Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #4417 holding.
  • UBS Group first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.